Role of angiotensin - converting enzyme inhibitors in early antihypertensive treatment in non - insulin dependent diabetes mellitus . 
<br>
<br> The effect of captopril monotherapy on <font color="blue">blood_1</font> <font color="blue">pressure_1</font> <font color="blue">and_1</font> <font color="blue">metabolism_1</font> was investigated in a placebo - controlled study in 30 non - insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run - in / drug ; placebo / wash - out ) on a metabolic ward . Captopril significantly reduced both <font color="blue">systolic_2</font> <font color="blue">and_2</font> <font color="blue">diastolic_2</font> <font color="blue">blood_2</font> <font color="blue">pressure_2</font> ( 154/90 + /- 5/2 vs. 144/86 + /- 4/3 mmHg ) without major side effects . <font color="blue">Mean_1</font> <font color="blue">run_1</font> <font color="blue">-_1</font> <font color="blue">in_1</font> <font color="blue">postprandial_3</font> <font color="blue">blood_3</font> <font color="blue">glucose_3</font> <font color="blue">concentrations_3</font> were also reduced upon ACE - inhibition ( 9 a.m. : 12.7 + /- 0.4 vs. 11.1 + /- 0.4 mmol / l ; 1 p.m. : 11.0 + /- 0.3 vs. 8.9 + /- 0.3 mmol / l ; P less than 0.05 ) , while <font color="blue">blood_2</font> <font color="blue">kinin_2</font> <font color="blue">concentrations_2</font> ( 40.0 + /- 2.5 pmol / l ) were approximately doubled ( 108.8 + /- 23.5 pmol / l ; P less than 0.05 ) . <font color="blue">Body_3</font> <font color="blue">mass_3</font> <font color="blue">index_3</font> <font color="blue">,_3</font> <font color="blue">fasting_3</font> <font color="blue">plasma_3</font> <font color="blue">insulin_3</font> <font color="blue">,_3</font> <font color="blue">serum_3</font> <font color="blue">electrolyte_3</font> <font color="blue">pattern_3</font> <font color="blue">,_3</font> <font color="blue">uric_3</font> <font color="blue">acid_3</font> <font color="blue">,_3</font> <font color="blue">white_3</font> <font color="blue">blood_3</font> <font color="blue">count_3</font> <font color="blue">,_3</font> <font color="blue">lipid_3</font> <font color="blue">profile_3</font> <font color="blue">as_2</font> <font color="blue">well_2</font> <font color="blue">as_2</font> <font color="blue">hepatic_2</font> <font color="blue">and_2</font> <font color="blue">renal_2</font> <font color="blue">function_2</font> <font color="blue">parameters_2</font> <font color="blue">remained_1</font> <font color="blue">unaltered_1</font> throughout the observation period . The data are in line with recent experimental studies showing a <font color="blue">beneficial_1</font> <font color="blue">metabolic_2</font> <font color="blue">effect_2</font> <font color="blue">of_1</font> <font color="blue">captopril_1</font> <font color="blue">in_1</font> <font color="blue">Type_1</font> <font color="blue">II_1</font> <font color="blue">diabetes_1</font> <font color="blue">._1</font> ACE inhibitors might therefore become first - line drugs in early <font color="blue">antihypertensive_1</font> intervention in Type II diabetic patients .